Hospital systems for the detection and prevention of adverse drug events.
Clin Pharmacol Ther. 2011 Jun;89(6):779-81
Authors: Cheng CM
In its 2006 report “Preventing Medication Errors,” the Institute of Medicine (IOM) …

[Read more →]

Related Articles

Drug dosing in patients with impaired renal function.

Clin Pharmacol Ther. 2009 Nov;86(5):483-9

Authors: Brater DC

Renal function can affect disposition and response to drugs in a variety of ways. This review discusses the principles underlying such responses, with particular emphasis on how changes in disposition parameters affect dosing decisions.

PMID: 19626002 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

A critical appraisal of the safety and efficacy of drug-eluting stents.

Clin Pharmacol Ther. 2009 May;85(5):474-80

Authors: Maluenda G, Lemesle G, Waksman R

Drug-eluting stents (DESs) have largely demonstrated their superiority to bare-metal stents (BMSs) with respect to in-stent restenosis. Since the US Food and Drug Administration (FDA) approved the first DES in 2003, there has been a significant increase in the use of these devices. They are used in 70-80% of all stent procedures worldwide. Nevertheless, safety concerns stemming from reports of increased risk of late stent thrombosis (ST) and myocardial infarction (MI) have tempered the enthusiasm that the advent of these stents originally generated. New generation DESs with novel polymers, antiproliferative drugs, and improved platforms are now approved and available for use. In this review we provide a critical appraisal, based on published clinical data, of the safety and efficacy of various DESs.

PMID: 19279567 [PubMed - indexed for MEDLINE]

[Read more →]